FRX Related Downgrades
-
JPMorgan Downgrades Forest Laboratories (FRX) to Neutral
-
Argus Downgrades Forest Laboratories (FRX) to Hold
-
Goldman Sachs Downgrades Forest Laboratories (FRX) to Sell
-
Caris & Co. Downgrades Forest Laboratories (FRX) to Above Average
-
Wedbush Downgrades Clinical Data (CLDA) to Neutral; Forest Buying CLDA for $30 Plus CVR,
-
Merriman Curhan Ford Downgrades Forest Laboratories (FRX) to Neutral
-
Citi Downgrades Forest Laboratories (FRX) to Hold
-
McNicoll Lewis & Vlak Downgrades Clinical Data (CLDA) to Hold; Acquired by Forest (FRX) at $30 per Share Plus Contingent Payments
-
Rodman & Renshaw Downgrades Clinical Data (CLDA) to Market Perform
-
Piper Jaffray Cuts Clinical Data (CLDA) to Neutral Amid Forest Labs Deal
-
Bernstein Downgrades Forest Laboratories (FRX) to Market Perform
-
Credit Agricole Downgrades Forest Labs (FRX) from Underperform to Sell
-
Morgan Stanley on Drug Manufacturers: Downgrades FRX; Upgrades WCRX
-
Forest Labs (FRX) Shares Modestly Lower Following Calyon's Earlier Downgrade to Underperform
-
Oppenheimer Downgrades Forest Labs (FRX) to Perform
-
Lazard Downgrades Forest Labs (FRX) to Hold, Cuts Price Target to $32
-
Piper Jaffray Downgrades Forest Laboratories (FRX) to Underweight; Negative Daxas Panel - Big Blow to Pipeline
-
Needham & Co Downgrades Forest Labs (FRX) to Hold
-
ARGUS Downgrades Forest Laboratories (FRX) to Hold After Recent Run-up
-
Goldman Sachs Downgrades Forest Laboratories (FRX) to Sell
-
JPMorgan Downgrades Forest Laboratories (FRX) to Underweight
-
UBS Downgrades Forest Labs (FRX) to Neutral
-
Credit Suisse Downgrades Forest Laboratories (FRX) to Neutral
-
S&P Equity Research Downgrades Forest Labs (FRX) to Hold
-
Friedman Billings Downgrades Forest Labs (FRX) to Market Perform
-
Goldman Sachs Downgrades Forest Labs (FRX) to Sell
-
Summary Of Today's Upgrades And Downgrades
-
Merrill Lynch downgrades Forest Laboratories (FRX) to Neutral
-
First Albany downgrades Forest Labs (FRX) to Neutral
-
Citigroup downgrades Forest Labs (FRX) to Sell
-
Buckingham Research Downgrades Forest Laboratories (FRX) to Neutral
-
Piper Jaffray downgrades Forest Laboratories Inc. (FRX) to Market Perform
-
WR Hambrecht downgrades Forest Laboratories Inc. (FRX) to Sell
-
Jefferies & Co Downgrades Forest Labs (FRX) to Hold
-
HSBC downgrades Forest Labs (FRX) to Underweight
-
Merrill Lynch downgrades Forest Labs (FRX) to Neutral
-
Citigroup Downgrades Forest Labs (FRX) to Hold
-
Am Tech Downgrades Forest Labs (FRX) to Hold
-
HSBC downgrades Forest labs (FRX) to Neutral
-
Credit Suisse Downgraded Forest Laboratories (FRX) to Underperform
-
Prudential downgrades FRX to Neutral
-
Morgan Stanley downgrades FRX to Equal-Weight
-
Thomas Weisel downgrades FRX to Peer Perform
-
Credit Suisse FB Downgrades Forest Labs
Back to FRX Stock Lookup
